Terumo (OTCMKTS:TRUMY) Hits New 1-Year Low – Time to Sell?

Terumo Corp. (OTCMKTS:TRUMY)’s stock price reached a new 52-week low on Friday . The company traded as low as $13.82 and last traded at $13.8410, with a volume of 75758 shares changing hands. The stock had previously closed at $14.06.

Terumo Stock Performance

The firm’s 50 day moving average is $15.01 and its 200 day moving average is $16.41. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.46 and a current ratio of 2.51. The stock has a market cap of $20.51 billion, a P/E ratio of 23.08 and a beta of 0.75.

Terumo (OTCMKTS:TRUMY) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $1.86 billion for the quarter, compared to analyst estimates of $1.75 billion. Terumo had a net margin of 12.35% and a return on equity of 9.39%.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.